Business
‘Not for the faint-hearted’: COVID crisis brings boom time for biotechs – Sydney Morning Herald
The pandemic has put the focus on Australia’s biotech sector where high risk, high reward is par for the course and regulators can make or break a company.
Normal text sizeLarger text sizeVery large text size
Mesoblast boss and major shareholder Silviu Itescu wont be the only one breathing easier now that the ASX-listed biotechs flagship treatment has managed to get the green light from the US regulators advisory committee.
It was a close run thing by all accounts and for Itescu and investors in Mesoblast a no vote would have seen a decades worth of work come to a standstill.
For his part, Itescu says he wasnt quite as spooked as investors by si…
-
General20 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Business20 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General21 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General23 hours agoAlbanese beats drum on economy as trade clouds gather